Form 4: Fractyl Health Director Ajay Royan Granted 22,500 Stock Options as Compensation

Fractyl Health, Inc. (GUTS) has reported that Director and 10% Owner Ajay Royan was granted 22,500 stock options as compensation for his board service.

Summary

• Ajay Royan, a Director and 10% Owner of Fractyl Health, Inc. (GUTS), was granted 22,500 stock options.
• The transaction date for this grant was June 11, 2025.
• The stock options have an exercise price of $2.27 per share.
• These options were awarded as compensation for Mr. Royan's service on the Issuer's board of directors, in accordance with the company's non-employee director compensation policy.
• The options will vest and become exercisable in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, subject to continued service as a non-employee director.
• The expiration date for these stock options is June 10, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) to a director. While not directly impacting financial performance, it reflects routine corporate governance and compensation practices. It's a neutral to slightly positive event as it aligns director incentives with shareholder value.

Positives

• The grant of stock options aligns with standard corporate governance practices for compensating non-employee directors, indicating a structured approach to board remuneration.
• The vesting schedule, tied to continued service, incentivizes long-term commitment from a key director and 10% owner.

Negatives

• The issuance of new stock options, while standard, can lead to potential dilution for existing shareholders if exercised, though the impact from this specific grant of 22,500 options is minimal.

Risks

• The value of the stock options is dependent on the future performance of Fractyl Health's common stock; if the stock price does not exceed the exercise price of $2.27, the options may not be in-the-money.
• Continued service on the board is a condition for vesting, meaning the options could be forfeited if the director's service ceases before the vesting date.

Future Outlook

The document indicates that the granted stock options will vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, subject to continued service, providing a future milestone for the options to become exercisable.

Management Comments

• The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy.

Industry Context

The grant of stock options to non-employee directors is a common practice across industries, particularly in the biotechnology and healthcare sectors where companies often use equity compensation to attract and retain experienced board members. This aligns with typical compensation structures for public companies.

Comparison to Industry Standards

• The grant of stock options as compensation for non-employee directors is a standard practice in the U.S. public company landscape, particularly for growth-oriented companies like those in the health sector.
• The vesting schedule (single installment on the earlier of next annual meeting or first anniversary) is a common approach for director equity grants, aiming to align director interests with long-term shareholder value while acknowledging the annual nature of board service.
• The exercise price of $2.27, presumably the fair market value on the grant date, is typical for compensatory options, ensuring they are 'at-the-money' at the time of grant.

Corporate Governance

Related Party Transactions

• The transaction involves a stock option grant to Ajay Royan, who is both a Director and a 10% Owner of Fractyl Health, Inc., making it a related party transaction as defined by SEC regulations.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also aligns the director's interests with long-term share price appreciation.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.
• Management: No direct impact mentioned, but demonstrates the company's established compensation policies for board members.

Next Steps

• The stock options will vest and become exercisable on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 11, 2025).

Key Dates

Recommendation

Keywords

Fractyl Health, GUTS, SEC Form 4, Stock Options, Director Compensation, Ajay Royan, Equity Grant, Beneficial Ownership, Corporate Governance